This review explores the evidence of myocardial and atrial inflammation in right heart disease and the potential relevance of targeting cytokines in future atrial fibrillation management strategies.
Atrial fibrillation (AF) is the most common cardiac arrhythmia responsible for increased risk of a stroke and sudden death. Right heart disease (RHD), characterized by myocardial dysfunction and structural alteration affecting the right ventricle and the right atrium, is recognized as an important risk factor for AF. Inflammation and cardiac fibrosis emerge as arrhythmogenic pathophysiological events commonly occurring in most diseases responsible for cardiac arrhythmias and AF. However, no commercially available anti-inflammatory drugs were shown to irreversibly cure AF. Hence, more investigations are required to identify the key inflammatory and fibrosis agents involved in arrhythmogenesis. In this review, we explore (i) the recent evidence of myocardial, and especially atrial, inflammation in RHD, and (ii) the relevance of targeting inflammatory and anti-inflammatory cytokines in future strategies, combined with current AF management, in RHD.
Khider et al. (Sun,) conducted a review in Right heart disease and atrial fibrillation. Targeting inflammatory and anti-inflammatory cytokines was evaluated. This review explores the evidence of myocardial and atrial inflammation in right heart disease and the potential relevance of targeting cytokines in future atrial fibrillation management strategies.